home / stock / lexx / lexx quote
Last: | $3.39 |
---|---|
Change Percent: | -1.28% |
Open: | $3.16 |
Close: | $3.39 |
High: | $3.52 |
Low: | $3.01 |
Volume: | 491,789 |
Last Trade Date Time: | 05/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.39 | $3.16 | $3.39 | $3.52 | $3.01 | 491,789 | 05-28-2024 |
$3.12 | $2.87 | $3.12 | $3.1896 | $2.86 | 223,654 | 05-27-2024 |
$3.12 | $2.87 | $3.12 | $3.1896 | $2.86 | 223,654 | 05-24-2024 |
$2.88 | $2.75 | $2.88 | $2.88 | $2.7277 | 345,581 | 05-23-2024 |
$2.75 | $2.92 | $2.75 | $2.9899 | $2.66 | 332,384 | 05-22-2024 |
$2.99 | $2.85 | $2.99 | $3.07 | $2.795 | 355,261 | 05-21-2024 |
$2.92 | $3.18 | $2.92 | $3.2 | $2.83 | 347,329 | 05-20-2024 |
$3.15 | $3.17 | $3.15 | $3.43 | $3.06 | 281,635 | 05-17-2024 |
$3.14 | $3.05 | $3.14 | $3.19 | $3.05 | 117,387 | 05-16-2024 |
$3.08 | $3.09 | $3.08 | $3.1465 | $3.025 | 174,453 | 05-15-2024 |
$3.08 | $3.13 | $3.08 | $3.26 | $3.055 | 101,842 | 05-14-2024 |
$3.18 | $3.62 | $3.18 | $3.62 | $3.14 | 231,565 | 05-13-2024 |
$3.55 | $3.62 | $3.55 | $4 | $3.52 | 256,011 | 05-10-2024 |
$3.6 | $3.6 | $3.6 | $3.81 | $3.42 | 192,366 | 05-09-2024 |
$3.54 | $3.39 | $3.54 | $3.5599 | $3.34 | 103,173 | 05-08-2024 |
$3.43 | $3.37 | $3.43 | $3.48 | $3.22 | 226,517 | 05-07-2024 |
$3.41 | $3.44 | $3.41 | $3.5099 | $3.18 | 293,532 | 05-06-2024 |
$3.13 | $3.05 | $3.13 | $3.24 | $2.93 | 111,594 | 05-03-2024 |
$3 | $3.5 | $3 | $3.53 | $2.95 | 185,054 | 05-02-2024 |
$3.49 | $3.06 | $3.49 | $3.68 | $3.06 | 363,282 | 05-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Company Name:
LEXX Stock Symbol:
NASDAQ Market:
Lexaria, a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 GLP-1, a class of drugs, has demonstrated the ability to address diabetes and weight loss, albeit with poor oral bioavaila...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is partnering with a contract research organization (“CRO”) to conduct its human pilot study #3. According to the announcement, this is the first-ever DehydraTECH(TM)-processed tirzepatide from...
(TheNewswire) First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format Kelowna, British Columbia – May 23, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company”...